What is the long-term trend for BridgeBio Pharma's noncontrolling interests in subsidiaries?

Over 5 years (2020 to 2025), BridgeBio Pharma's noncontrolling interests in subsidiaries has grown at a -26.2% compound annual growth rate (CAGR), from $48.35M to $10.6M.

BridgeBio Pharma BBIO Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Bristol-Myers SquibbBMY

$34M-42.4%

PfizerPFE

——

Roivant SciencesROIV

——

Royalty PharmaRPRX

——

Arrowhead ResearchARWR

——

AbbVieABBV

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's noncontrolling interests in subsidiaries?: BridgeBio Pharma (BBIO) reported noncontrolling interests in subsidiaries of $10.44M in Q1 2026.
How has BridgeBio Pharma's noncontrolling interests in subsidiaries changed year-over-year?: BridgeBio Pharma's noncontrolling interests in subsidiaries increased by 4.8% year-over-year, from $9.96M to $10.44M.
What is the long-term trend for BridgeBio Pharma's noncontrolling interests in subsidiaries?: Over 5 years (2020 to 2025), BridgeBio Pharma's noncontrolling interests in subsidiaries has grown at a -26.2% compound annual growth rate (CAGR), from $48.35M to $10.6M.